2-(三氟甲基)吗啉 | 1196532-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 2-(三氟甲基)吗啉
• 英文名称: 2-(trifluoromethyl)morpholine
• CAS: 1196532-95-2
• 化学式: C₅H₈F₃NO
• mdl: MFCD19597220
• 分子量: 155.12
• InChiKey: OVAZCYUQNNFOKS-UHFFFAOYSA-N

物化性质

• 沸点：
  128.5±35.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(三氟甲基)吗啉 在 盐酸 、 三乙胺 作用下， 以 水 、 异丙醇 、 丙酮 为溶剂， 反应 6.5h， 生成 4-(4-phenylthiazol-2-yl)-2-(trifluoromethyl)morpholine
  参考文献：
  名称：

  [EN] QUORUM SENSING INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE DÉTECTION DE QUORUM ET MÉTHODES D'UTILISATION

  摘要：

  抑制革兰氏阴性细菌特别是弧菌属的群体感应的某些化合物被揭示。还提供了用于治疗细菌感染的组合物和治疗此类感染的方法。

  公开号：

  WO2022036282A1

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• [EN] QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS QUINOLÉINE CARBOXAMIDES ET QUINOLÉINE CARBONITRILES EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR2, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2013066736A1

  公开（公告）日：2013-05-10

  The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了式(I)喹啉甲酰胺和喹啉腈化合物，其中环A，RQ，-L-，R1，n，R2和R3的定义如本文所述。本发明的化合物可用作非竞争性mGluR2拮抗剂或mGluR2负变构调节剂(NAMs)，并且用于治疗患者(最好是人类)的疾病或失调的方法，其中涉及mGluR2-NAM受体，如阿尔茨海默病，认知障碍，精神分裂症和其他情绪障碍，疼痛障碍和睡眠障碍，通过向患者投给治疗有效量的本发明化合物或其药用可接受的盐。本发明还涉及包含本发明化合物或其药用可接受的盐(可选地与一个或多个其他活性成分组合)和药用可接受载体的药物组合物，以及使用本发明的化合物和药物组合物治疗这些疾病。
• [EN] IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE PRÉSENTANT DES PROPRIÉTÉS ANTAGONISTES DU A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2019118313A1

  公开（公告）日：2019-06-20

  Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  本文披露了具有Formula I结构的化合物，或者其任何药学上可接受的盐：其中：“Z”和R1在此有定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度发现的受体。据信，这些化合物和药物配方在治疗或管理神经退行性疾病，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍方面是有用的。
• Substituted annellated pyrimidines and use thereof
  申请人：FOLLMANN Markus

  公开号：US20130338137A1

  公开（公告）日：2013-12-19

  The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating and/or preventing diseases, in particular for treating and/or preventing cardiovascular diseases.

  本申请涉及新型取代的螺合嘧啶类化合物，其生产方法，单独或组合使用用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物产品的用途，特别是用于治疗和/或预防心血管疾病。